May 1, 2026 Log in

News

[Unicocell Biomed] May 2026 Revenue Reaches NT$1.425 Million (Up 52.4% YoY)

Q: 向榮生技2026年5月的營收較去年同期有何變化？

營收較去年同期增加了52.4%。

Citation-Grade Primary-source linked Schema.org verified NQ 40 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 1, 2026 9:00 AM ・ Updated Jun 14, 2026 12:08 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Unicocell Biomed (6794) announced its consolidated revenue for May 2026 at NT$1.425 million (approx.

Unicocell Biomed (6794) announced its consolidated revenue for May 2026 at NT$1.425 million (approx. NT$10 million), representing a significant year-on-year increase of 52.4%.

PRIMARY SOURCE PR Times View source Distributor: PR Times
Published: May 1, 2026

According to the financial disclosure of Unicocell Biomed (Company Code: 6794), a company classified under the Biotechnology and Medical Care industry, the consolidated revenue for May 2026 was NT$1,425 thousand (approximately NT$0.01 hundred million). This represents a year-on-year growth rate of +52.4% compared to the same month last year. The company is actively engaged in the development of regenerative medicine and stem cell therapies.

FACT BOX

Source: PR Times
Category: News
Products / services: ELIXCYTE®

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 1, 2026 9:00 AM — Distributor PR Times
Collected　Jun 12, 2026 8:00 AM
AI structured & analyzed　Jun 12, 2026 1:50 PM
Desk-reviewed & published　May 1, 2026 9:00 AM

FAQ

向榮生技2026年5月的單月營收是多少？

向榮生技2026年5月的單月營收為新台幣142.5萬元（約0.01億元）。

向榮生技2026年5月的營收較去年同期有何變化？

營收較去年同期增加了52.4%。

向榮生技所屬的產業類別是什麼？

向榮生技所屬產業類別為生技醫療業，主要專注於再生醫學及幹細胞技術。

向榮生技的公司代號是多少？

向榮生技的台灣證券交易所公司代號為6794。

向榮生技的核心業務有哪些？

主要包括幹細胞新藥研發（如ELIXCYTE®）、幹細胞分泌物（外泌體）及細胞生產技術服務（CDMO）。

Cite this article — HOW TO CITE

Washin AI News Desk“[Unicocell Biomed] May 2026 Revenue Reaches NT$1.425 Million (Up 52.4% YoY)”AI News by Washin Village（和心村）, May 1, 2026. https://aeo.washinmura.jp/ai/%E5%90%91%E6%A6%AE%E7%94%9F%E6%8A%80/en/news/2026-05-01-%E5%90%91%E6%A6%AE%E7%94%9F%E6%8A%80-2026-05-%E6%9C%88%E7%87%9F%E6%94%B6-0-01%E5%84%84-%E5%B9%B4%E5%A2%9E-52-4

AI CRAWLER ACTIVITY

as of Jul 4, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

ClaudeBot

bot_visits_summary

4615k

last Jul 4, 2026

GPTBot

bot_visits_summary

3210k

last Jul 4, 2026

Bingbot

bot_visits_summary

1955k

last Jul 4, 2026

Google AI

bot_visits_summary

1684k

last Jul 4, 2026

Applebot

bot_visits_summary

1374k

last Jul 4, 2026

Googlebot

bot_visits_summary

1278k

last Jul 4, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 向榮生技 Back to newsroom (92)

Copied